Hyperkalemia Risk with Losartan

Introduction to Hyperkalemia Risk

Losartan, an angiotensin II receptor blocker (ARB), can cause hyperkalemia (high potassium levels) by decreasing potassium excretion through inhibition of the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD) or diabetes mellitus 1

Patients with chronic kidney disease (CKD) are at increased risk of developing hyperkalemia while on losartan, with the risk increasing with declining renal function 2
Diabetes mellitus amplifies the risk of hyperkalemia with ARBs, such as losartan 2
Concomitant medications that raise potassium levels, including potassium-sparing diuretics, other RAAS inhibitors, NSAIDs, trimethoprim-sulfamethoxazole, and potassium supplements, increase the risk of hyperkalemia 1
High potassium intake from diet or supplements also increases the risk of hyperkalemia 1

The incidence of hyperkalemia with losartan varies depending on patient characteristics, with <2% incidence in patients without risk factors 2
In patients with heart failure and diabetes, the incidence of hyperkalemia can be up to 11.8% for potassium >5.5 mmol/L and 4% for severe hyperkalemia (>6.0 mmol/L) 2

The European Society of Cardiology recommends initiating RAAS inhibitors, such as losartan, at low doses in patients with risk factors and titrating gradually with careful monitoring of renal function and potassium levels 2
Patient education is crucial, including avoiding over-the-counter potassium supplements, limiting potassium-based salt substitutes, being cautious with high-potassium foods, and avoiding NSAIDs when possible 2

Dual RAAS blockade, combining losartan with ACE inhibitors or direct renin inhibitors, significantly increases hyperkalemia risk and is generally discouraged 2
Triple therapy, combining an ACE inhibitor, ARB, and mineralocorticoid receptor antagonist, should be avoided due to very high hyperkalemia risk 2